Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$41.89 USD
+1.55 (3.84%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $41.89 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Janux Therapeutics, Inc. [JANX]
Reports for Purchase
Showing records 21 - 33 ( 33 total )
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Execution is the Name of the Game
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating with an OUTPERFORM and $24 PT: Can a TRACTr be a Trojan Horse?
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Peek at JANX-007 Clinical Data in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JANX-007 Dosing Initiated; Pipeline Progress Steadily; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First IND Cleared; Pipeline Milestones Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Advancing Pipeline Into Clinical Stage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progressing As Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Development of TRACTrs Remains on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Janux Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Immunotherapy Player With a Game-Changing TCell Engager Platform; Initiate With Buy and a $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S